Cytodyn (CYDY) Stock Price
Cytodyn Price
For Cytodyn, the net margin of -79,255.6% is down versus 3,525.7% a few years ago.
Cytodyn stock price
Cytodyn business model & stock analysis
Frequently asked questions about Cytodyn
The primary business model of Cytodyn Inc., a biotechnology company, focuses on the development and commercialization of innovative therapies to treat various medical conditions. Cytodyn specializes in the application of monoclonal antibodies and other therapeutic approaches to target specific diseases, including HIV, cancer, and immunological disorders. Cytodyn's dedication to research and development enables them to create advanced solutions that aim to improve patient outcomes and tackle unmet medical needs. Through strategic partnerships and collaborations, Cytodyn Inc. aims to deliver breakthrough treatments and positively impact the healthcare industry.
Cytodyn Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Cytodyn Inc in the market are pharmaceutical companies such as Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Merck & Co., Inc. These companies also focus on the development and commercialization of innovative therapeutics, similar to Cytodyn. However, Cytodyn differentiates itself through its unique drug candidates, including Leronlimab, which targets multiple indications such as HIV, cancer, and immunological disorders. Despite the competition, Cytodyn strives to carve its niche in the pharmaceutical industry by delivering groundbreaking therapies with the potential to revolutionize patient care and improve outcomes.
Cytodyn Inc is a biotechnology company with a history dating back to 2002. It specializes in the development of innovative therapies for patients with unmet medical needs, particularly in the areas of cancer, HIV, and immunology. The company's focus lies in the development of monoclonal antibody-based treatments that aim to improve patients' quality of life. Cytodyn Inc has made significant strides in its research and development efforts, consistently working towards bringing potentially life-saving treatments to market. With a dedicated team and a strong commitment to scientific advancements, Cytodyn Inc continues to push the boundaries of biotechnology and deliver promising outcomes for patients worldwide.
Cytodyn Inc has achieved several significant milestones. The company successfully developed PRO 140, a monoclonal antibody targeting CCR5, which received Fast Track designation from the FDA for HIV-infected patients. Additionally, Cytodyn obtained positive results from pivotal Phase 3 trials of PRO 140 for HIV treatment, showing superior efficacy and safety compared to existing therapies. The company has also explored the therapeutic potential of PRO 140 in different indications, including metastatic triple-negative breast cancer and graft-versus-host disease. These achievements highlight Cytodyn Inc's commitment to pioneering innovative treatments that address critical medical needs.
Cytodyn Inc is primarily present in the United States.
Cytodyn Inc is a biotechnology company dedicated to revolutionizing the treatment landscape for various diseases. Focused on innovative therapies, Cytodyn prioritizes patient well-being, scientific excellence, and ethical conduct. The company's corporate philosophy centers around developing cutting-edge solutions that address unmet medical needs and improve the quality of patients' lives. With an unwavering commitment to research and development, Cytodyn strives to foster collaborations, enhance healthcare accessibility, and drive global healthcare improvements. By adhering to its core values of integrity, innovation, and compassion, Cytodyn Inc continuously seeks to make a positive impact in the field of biotechnology.
6 analysts currently rate the Cytodyn stock: 0 recommend buying, 3 holding and 3 selling.
Converted at the current exchange rate, the Cytodyn share trades at 0.18 EUR (0.20 USD).
The Cytodyn share (CYDY) is listed on 3 stock exchanges, including: München (296.MU).
Cytodyn Inc is an international biopharmaceutical company specializing in the development of innovative therapies and technologies in the field of immunotherapy. The company was founded in 2002 and is headquartered in Vancouver, Canada. Cytodyn Inc's business activities are divided into three areas: research and development, clinical trials, and marketing. In the research and development area, the company focuses on developing biotechnology products for the treatment of infectious diseases, autoimmune diseases, and cancer. These are highly specialized therapies based on strengthening the immune system. One important product of the company is the HIV blocker program "PRO 140" - a monoclonal antibody that can offer HIV-infected patients a rare but life-changing chance for viral suppression. In addition, the company is working on other innovative therapy approaches, such as the treatment of graft-versus-host diseases (GvHD), which occur in many patients who have undergone stem cell transplantation. In the context of clinical trials, the company tests its products and technologies in collaboration with leading universities and research institutions worldwide. It relies on strict quality controls and compliance with all regulatory requirements. The goal is to prove the safety and efficacy of the therapies and bring them to market readiness. Cytodyn Inc's marketing activities are carried out through a wide range of distribution and marketing channels. The company collaborates with leading distribution partners and medical facilities worldwide to make its products available to customers. It also focuses on targeted marketing to continuously expand the awareness of its product range. Cytodyn Inc. follows a growth model that promotes collaborative partnerships in the areas of research, development, and marketing. The company works with various partners to accelerate the development of new therapies and technologies and to capitalize on international business opportunities. The goal is to fully harness the potential of immunotherapy and make a significant contribution to improving healthcare worldwide. To optimize search results, this text is SEO-optimized and contains targeted keywords.
The revenue cannot currently be calculated for Cytodyn.
The profit of Cytodyn is -42.70 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cytodyn is currently -6.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cytodyn stock.
The P/S cannot be calculated for Cytodyn currently.
The Eulerpool Quality Score for Cytodyn is 1/10.
The ISIN of Cytodyn is US23283M1018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cytodyn is A0YHA5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cytodyn is CYDY. The ticker symbol is used to trade Cytodyn shares on the stock exchange.
Cytodyn stock
Cytodyn Ticker
Cytodyn FIGI
All fundamentals and in-depth analysis of Cytodyn
Our stock analysis for Cytodyn stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytodyn. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.